To support tenants using AI, life sciences buildings need increased slab loads, electricity and water, all expensive upgrades for owners.

As the AI trade gets overheated and calls for some sort of bursting of the AI bubble grow louder, it might make sense to look ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

After taking a shot at becoming a neuroscience biotech, buzzy Bay Area AI outfit Verge Genomics is dropping its only clinical ...

An investor whose portfolio contains some value- or income-focused investments and some growth-oriented investments, who ...

Looking for the stock market outlook for the first half of 2026? See what you should consider heading into the new year to ...

With all the buzzwords surrounding artificial intelligence, from smiling promotions to angry chagrins—promises that it will ...

On December 17, 2025, IO Biotech, Inc. received a notice from Nasdaq that its common stock no longer met the Nasdaq Global Select Market’s minimum bid price requirement, as its closing bid price had ...

E.F. Hutton is proud to have served as an Exclusive M&A Advisor in the recently completed merger between Apimeds ...

Explore the potential of CKD drug ISM4808 and its role in treating chronic kidney disease through innovative research.

Chai is building foundation models for drug discovery, specifically to predict interactions between molecules so they could be reprogramed for cures.

Tech entrepreneur Bryan Johnson aims for biological immortality by 2039, driven by AI's acceleration of biotech and ...